Overview

A Study Of The Selective PKC-β Inhibitor MS- 553

Status:
Recruiting
Trial end date:
2023-02-25
Target enrollment:
Participant gender:
Summary
A Phase I Dose-Escalation Study Of The Selective PKC-Β Inhibitor MS-553 In Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase:
Phase 1
Details
Lead Sponsor:
MingSight Pharmaceuticals, Inc.